Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Amstutz, Ursula; Henricks, Linda M; Offer, Steven M; Barbarino, Julia; Schellens, Jan H M; Swen, Jesse J; Klein, Teri E; McLeod, Howard L; Caudle, Kelly E; Diasio, Robert B; Schwab, Matthias (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical pharmacology and therapeutics, 103(2), pp. 210-216. Wiley 10.1002/cpt.911

Text Amstutz_et_al-2018-Clinical_Pharmacology_&_Therapeutics.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (145kB) | Request a copy

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

Interest & Impact

Downloads

1 since deposited on 05 Mar 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item